Last updated: July 17, 2026

Application No. 19/407,141

LIGAND-DRUG CONJUGATES

Non-Final OA

Filed

Dec 03, 2025

Priority

Dec 04, 2024 — provisional 63/728,044

Examiner

PUTTLITZ, KARL J

Art Unit

1646

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Tripartite Therapeutics Inc.

OA Round

1 (Non-Final)

Interview Optional

— +18.5% interview lift. Examiner has a relatively high allowance rate (69%); +18.5% interview lift. A written response may suffice.

Based on 1421 resolved cases, 2023–2026

Examiner Intelligence

PUTTLITZ, KARL J View full profile →

Grants 69% — above average

Career Allowance Rate

982 granted / 1421 resolved

+9.1% vs TC avg

Strong +18% interview lift

Without

With

+18.5%

Interview Lift

resolved cases with interview

Typical timeline

2y 6m

Avg Prosecution

57 currently pending

Career history

1477

Total Applications

across all art units

Statute-Specific Performance

§101

1.0%

-39.0% vs TC avg

§103

42.4%

+2.4% vs TC avg

§102

8.3%

-31.7% vs TC avg

§112

12.5%

-27.5% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1421 resolved cases

Prosecution Timeline

Dec 03, 2025

Application Filed

Jun 05, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/001,004

Patent 12679822

ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

3y 7m to grant Granted Jul 14, 2026

18/038,812

Patent 12678513

ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF

3y 1m to grant Granted Jul 14, 2026

17/596,106

Patent 12673113

METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-TARGETED ADJUVANTS

4y 7m to grant Granted Jul 07, 2026

18/338,878

Patent 12674003

SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES

3y 0m to grant Granted Jul 07, 2026

17/637,924

Patent 12653896

TARGETED DENDRIMER CONJUGATES

4y 3m to grant Granted Jun 16, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

69%

Grant Probability

88%

With Interview (+18.5%)

2y 6m (~1y 11m remaining)

Median Time to Grant

Low

PTA Risk

Based on 1421 resolved cases by this examiner. Grant probability derived from career allowance rate.